SCHEMBL14699615

SCHEMBL14699615

CN(C)/N=N/c1ccc(C(=O)c2ccccc2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 7/20 0.55
▸ MAPT P10636 6/20 0.55
▸ NPC1 O15118 4/20 0.55
▸ HPGD P15428 3/20 0.55
▸ ALDH1A1 P00352 6/20 0.50
▸ TRPA1 O75762 1/20 0.48
▸ SRD5A2 P31213 1/20 0.48
▸ MEN1 O00255 3/20 0.46
▸ KMT2A Q03164 3/20 0.46
▸ L3MBTL1 Q9Y468 3/20 0.46
▸ POLB P06746 2/20 0.46
▸ LMNA P02545 2/20 0.46
▸ CASP3 P42574 1/20 0.46
▸ SENP8 Q96LD8 1/20 0.46
▸ SENP7 Q9BQF6 1/20 0.46
▸ SENP6 Q9GZR1 1/20 0.46
▸ GAA P10253 1/20 0.46
▸ HTT P42858 1/20 0.46
▸ BLM P54132 1/20 0.46
▸ ELANE P08246 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14699621 1.00 RAB9A (0.55) RAB9AMAPTNPC1HPGDALDH1A1
SCHEMBL17988727 0.86 ALDH1A1 (0.61) RAB9AMAPTNPC1HPGDALDH1A1
SCHEMBL12817727 0.86 MAPT (0.55) RAB9AMAPTNPC1HPGDALDH1A1
SCHEMBL14699617 0.86 MAPT (0.55) RAB9AMAPTNPC1HPGDALDH1A1
SCHEMBL14699619 0.86 MAPT (0.55) RAB9AMAPTNPC1HPGDALDH1A1
SCHEMBL17988682 0.84 FASN (0.51) RAB9AMAPTNPC1HPGDALDH1A1
SCHEMBL4060546 0.83 NPC1 (0.65) RAB9AMAPTNPC1ALDH1A1TRPA1
SCHEMBL8655588 0.83 NPC1 (0.65) RAB9AMAPTNPC1ALDH1A1TRPA1
SCHEMBL38787 0.81 MAPT (0.55) RAB9AMAPTNPC1HPGDALDH1A1
SCHEMBL14699620 0.81 MAPT (0.55) RAB9AMAPTNPC1HPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230355644-A1 ACTIVE INGREDIENTS AND DRUGS FOR THE THERAPY OF VIRAL DISEASES, ESPECIALLY CORONA INFECTIONS, ESPECIALLY COVID-19 CREATIVE THERAPEUTICS GMBH (DE) 2023-11-09 — — US disclosed
US-20230355644-A1 ACTIVE INGREDIENTS AND DRUGS FOR THE THERAPY OF VIRAL DISEASES, ESPECIALLY CORONA INFECTIONS, ESPECIALLY COVID-19 CREATIVE THERAPEUTICS GMBH (DE) 2023-11-09 — — US disclosed
WO-2022063549-A1 ACTIVE SUBSTANCES AND DRUGS FOR THERAPY OF VIRAL DISEASES, PARTICULARLY CORONA INFECTIONS, MORE PARTICULARLY COVID-19 CREATIVE THERAPEUTICS GMBH (DE) 2022-03-31 — — WO disclosed
EP-2557075-A1 New triazene compounds for treating cancer Trin Therapeutics GmbH (DE) 2013-02-13 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230355644-A1 ACTIVE INGREDIENTS AND DRUGS FOR THE THERAPY OF VIRAL DISEASES, ESPECIALLY CORONA INFECTIONS, ESPECIALLY COVID-19 ACE, ACE2, SARS1 RAB9A 2059/4885MAPT 847/4885NPC1 298/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback